New target explored for psychiatric drug development
From the WUSTL Newsroom… In a surprising discovery, neuroscientists have found that a breakdown product of cholesterol in the brain may be a target for developing new drugs to treat schizophrenia and other mental illnesses. Although the research is in its early stages, the finding comes at a crucial time. Most existing drugs to treat schizophrenia work in similar ways, targeting dopamine receptors in the brain, but many patients don’t respond well to the medications or … Read More
Posted in: Axon Injury & Repair
Faculty: Charles Zorumski
